A Parallel, Placebo-Controlled, Randomized (2:1) Double-Blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-Monthly Versus Placebo on LS BMD in Men With Osteoporosis.

Trial Profile

A Parallel, Placebo-Controlled, Randomized (2:1) Double-Blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-Monthly Versus Placebo on LS BMD in Men With Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2010

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Male osteoporosis
  • Focus Therapeutic Use
  • Acronyms STRONG
  • Sponsors Roche
  • Most Recent Events

    • 01 Apr 2010 Primary endpoint 'Lumbar spine bone mineral density' has been met.
    • 01 Apr 2010 Results were published in Bone; Volume 46, Issue 4, April 2010.
    • 29 Dec 2009 Actual patient number changed from 132 to 135 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top